The Hypopharyngeal Cancer drugs in development market research report provides comprehensive information on the therapeutics under development for Hypopharyngeal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hypopharyngeal Cancer. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hypopharyngeal Cancer and features dormant and discontinued products.
GlobalData tracks 95 drugs in development for Hypopharyngeal Cancer by 66 companies/universities/institutes. The top development phase for Hypopharyngeal Cancer is phase ii with 60 drugs in that stage. The Hypopharyngeal Cancer pipeline has 94 drugs in development by companies and one by universities/ institutes. Some of the companies in the Hypopharyngeal Cancer pipeline products market are: AstraZeneca, BeiGene and CSPC Pharmaceutical Group.
The key targets in the Hypopharyngeal Cancer pipeline products market include Programmed Cell Death Protein 1, Epidermal Growth Factor Receptor ERB1, and Tubulin.
The key mechanisms of action in the Hypopharyngeal Cancer pipeline product include Programmed Cell Death Protein 1 Antagonist with 18 drugs in Phase III. The Hypopharyngeal Cancer pipeline products include 17 routes of administration with the top ROA being Intravenous and 14 key molecule types in the Hypopharyngeal Cancer pipeline products market including Monoclonal Antibody, and Small Molecule.
Hypopharyngeal Cancer overview
Hypopharyngeal cancer is a term used for tumors of a subsite of the upper aerodigestive tract, and like most other subsite designations, the distinction is anatomic rather than pathophysiologic within the group of head and neck malignancies. The hypopharynx is the region between the oropharynx above (at the level of the hyoid bone) and the esophageal inlet below (at the lower end of the cricoid cartilage). Embryologically, the larynx interjects into the hypopharynx anteriorly and is therefore considered a separate structure.
For a complete picture of Hypopharyngeal Cancer’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
